GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

Dr_Monkeybreath Aug. 21 at 5:18 PM

$GTBP is gonna spike very soon. ⏳📈💰

1 · Reply

gghh11 Aug. 20 at 9:56 PM

$GTBP This F’n POS stock / company is run by a bunch of criminals!! Looks like they will be delisted AGAIN!! MF’ers!! All of them are liars and criminals!!

1 · Reply

Dr_Monkeybreath Aug. 20 at 5:23 PM

$GTBP 1,500 @ $1.20. 🔒

0 · Reply

smoketuna Aug. 19 at 10:33 AM

$GTBP 89% with 🎯 TunaSignal.ai score! while price $1.54 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

NathanNat Aug. 11 at 5:34 PM

$GTBP today’s press release sounded good but I guess nobody cares what this company says anymore.

1 · Reply

Beastmade Jul. 14 at 9:49 PM

$GTBP What in the mk ultra.

0 · Reply

DrWodo Jul. 8 at 3:16 PM

$GTBP ouch

0 · Reply

AB5HUNNID Jul. 7 at 9:08 PM

$GTBP Double bottom at 2.16. Might just jump in tomorrow for a rebound

0 · Reply

DrWodo Jul. 7 at 12:28 PM

$GTBP down 20% last week. No news. What gives?

0 · Reply

Doozio Jul. 3 at 3:25 PM

$GTBP only 🐑 follow.

1 · Reply

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 13 days ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 2 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 3 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 6 months ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 10 months ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 11 months ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 11 months ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 1 year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 1 year ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 1 year ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 1 year ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 1 year ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 2 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 2 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 2 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Mar 28, 2022, 4:15 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 9, 2022, 4:24 PM EST - 3 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 3, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Feb 24, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 18, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Jan 20, 2022, 7:30 AM EST - 3 years ago

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

Jan 6, 2022, 4:30 PM EST - 3 years ago

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dr_Monkeybreath Aug. 21 at 5:18 PM

$GTBP is gonna spike very soon. ⏳📈💰

1 · Reply

gghh11 Aug. 20 at 9:56 PM

$GTBP This F’n POS stock / company is run by a bunch of criminals!! Looks like they will be delisted AGAIN!! MF’ers!! All of them are liars and criminals!!

1 · Reply

Dr_Monkeybreath Aug. 20 at 5:23 PM

$GTBP 1,500 @ $1.20. 🔒

0 · Reply

smoketuna Aug. 19 at 10:33 AM

$GTBP 89% with 🎯 TunaSignal.ai score! while price $1.54 - Catch the Big Movers Before They Break Out - Powered by AI

0 · Reply

NathanNat Aug. 11 at 5:34 PM

$GTBP today’s press release sounded good but I guess nobody cares what this company says anymore.

1 · Reply

Beastmade Jul. 14 at 9:49 PM

$GTBP What in the mk ultra.

0 · Reply

DrWodo Jul. 8 at 3:16 PM

$GTBP ouch

0 · Reply

AB5HUNNID Jul. 7 at 9:08 PM

$GTBP Double bottom at 2.16. Might just jump in tomorrow for a rebound

0 · Reply

DrWodo Jul. 7 at 12:28 PM

$GTBP down 20% last week. No news. What gives?

0 · Reply

Doozio Jul. 3 at 3:25 PM

$GTBP only 🐑 follow.

1 · Reply

PAS_Trader Jul. 3 at 3:19 PM

$GTBP good luck to your followers 🤣🤣🤣🤣

0 · Reply

Doozio Jun. 26 at 3:40 PM

$GTBP let’s bang bro.

0 · Reply

bullbuster269 Jun. 26 at 2:52 PM

$GTBP $ALXO $ERAS $MOLN $SLDB

0 · Reply

L_Tradez Jun. 26 at 12:54 AM

$GTBP

0 · Reply

kshonstocks Jun. 24 at 3:58 PM

$GTBP hitting scans, has higher highs

0 · Reply

BiopharmaWatch_com Jun. 16 at 6:14 PM

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

0 · Reply

QuiverQuant Jun. 13 at 2:57 PM

GT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of Directors Read more on $GTBP: https://www.quiverquant.com/news/GT+Biopharma%2C+Inc.+Appoints+David+C.+Mun-Gavin+to+Board+of+Directors

0 · Reply

Beastmade Jun. 11 at 3:48 PM

$GTBP What in the MK ultra am I making money on?

1 · Reply

Beastmade Jun. 11 at 12:04 AM

$GTBP Shoutout to truth social for putting me on this.

0 · Reply

PhishTourFunds Jun. 9 at 9:24 PM

$GTBP Steady as she goes

1 · Reply

kshonstocks Jun. 9 at 5:33 PM

$GTBP hitting scans, higher highs

0 · Reply

nassermahashir May. 28 at 10:20 AM

$GTBP wild runner will be here 🤑🤑🤑

0 · Reply

Market Cap	3.95M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	96,100
Avg Vol	102,122
Day's Range	N/A - N/A
Shares Out	3.56M
Stochastic %K	19%
Beta	1.33
Analysts	Sell
Price Target	$11.00